At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Ruxolitinibdrug
Likely dose
Ruxolitinib 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jun 19, 2015·Updated Nov 4, 2021
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for HIV Infections. Completed, enrolled 60 participants across 14 sites.
Detailed Summary
The purpose of this study was to evaluate the safety and tolerability of ruxolitinib in HIV-positive adults who were virologically suppressed and who were on antiretroviral therapy (ART).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartMay 2016
Primary CompletionFeb 2018
Study CompletionApr 2018
TodayJul 2026
First PostedJun 19, 2015
Enrollment StartMay 16, 2016
Primary CompletionFeb 18, 2018
Study CompletionApr 4, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.0 years ago
Interventions
Ruxolitinibdrug
10 mg orally twice daily for 5 weeks